Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action.

IF 4.2 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiac Failure Review Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI:10.15420/cfr.2024.06

Aleksandra Bykova, Maria Serova, Maria Chashkina, Raisa Kosharnaya, Zukhra Salpagarova, Denis Andreev, Ilya Giverts

{"title":"Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action.","authors":"Aleksandra Bykova, Maria Serova, Maria Chashkina, Raisa Kosharnaya, Zukhra Salpagarova, Denis Andreev, Ilya Giverts","doi":"10.15420/cfr.2024.06","DOIUrl":null,"url":null,"abstract":"<p><p>This review examines the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on different heart failure phenotypes with preserved ejection fraction (HFpEF). Traditional heart failure treatment modalities have shown limited success in improving outcomes for patients with HFpEF, but new evidence suggests that GLP-1RAs could be beneficial. The positive effects of GLP-1RAs are likely due to their ability to reduce systemic inflammation, enhance metabolism and directly affect the cardiovascular system, addressing critical aspects of HFpEF pathology. However, the exact impact of GLP-1RAs on clinical outcomes for different HFpEF phenotypes is still unclear. This review highlights both the potential benefits and the current limitations of GLP-1RA therapy, suggesting a careful approach for their application in clinical practice.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"10 ","pages":"e14"},"PeriodicalIF":4.2000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539042/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiac Failure Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/cfr.2024.06","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

This review examines the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on different heart failure phenotypes with preserved ejection fraction (HFpEF). Traditional heart failure treatment modalities have shown limited success in improving outcomes for patients with HFpEF, but new evidence suggests that GLP-1RAs could be beneficial. The positive effects of GLP-1RAs are likely due to their ability to reduce systemic inflammation, enhance metabolism and directly affect the cardiovascular system, addressing critical aspects of HFpEF pathology. However, the exact impact of GLP-1RAs on clinical outcomes for different HFpEF phenotypes is still unclear. This review highlights both the potential benefits and the current limitations of GLP-1RA therapy, suggesting a careful approach for their application in clinical practice.

查看原文本刊更多论文

胰高血糖素样肽-1 受体激动剂在多种射血分数保留型心力衰竭病理生理学中的应用：潜在益处和作用机制。

本综述探讨了胰高血糖素样肽-1 受体激动剂（GLP-1RA）对不同射血分数保留型心力衰竭（HFpEF）表型的影响。传统的心力衰竭治疗方法在改善 HFpEF 患者的预后方面效果有限，但新的证据表明 GLP-1RAs 可为患者带来益处。GLP-1RAs 的积极作用可能是由于它们能够减轻全身炎症、促进新陈代谢并直接影响心血管系统，从而解决了 HFpEF 病理学的关键问题。然而，GLP-1RA 对不同 HFpEF 表型临床结果的确切影响仍不清楚。本综述强调了 GLP-1RA 疗法的潜在益处和目前的局限性，建议在临床实践中谨慎应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiac Failure Review

CiteScore

5.60

自引率

0.00%

发文量

审稿时长

9 weeks